GET DAILY SIGNALSCoherus BioSciences (CHRS) Down -27% Over Three Months: Oncology Transition After CVR Payout
Key Takeaways
- CHRS traded near $1.07 in late October 2026, down roughly 5% from its late-September level of about $1.13.
- Over the trailing three months, shares have pulled back from the mid-$1.40s, a decline of approximately 27%.
- The company's special contingent value rights (CVR) dividend, with a record date of September 30, 2026 and a distribution date of October 7, 2026, completed its exit from legacy biosimilar assets.
- LOQTORZI net sales rose 15% quarter-over-quarter to $13.6 million in Q2 2026, and full-year 2026 revenue guidance was reiterated at $57–62 million.
- Sell-side coverage remains constructive, with recent Buy ratings carrying price targets well above the current share price.
- Near-term catalysts include oncology pipeline data readouts and the next quarterly earnings report.
Current Market Snapshot
Coherus BioSciences shares have settled into a sub-$1.10 range in late October 2026, closing near $1.07. The 30-day move is relatively muted at roughly negative 5%, reflecting a stock that has digested the completion of its corporate transformation rather than reacting to a single sharp catalyst. The broader quarterly picture is more pronounced: from the mid-$1.40s recorded in late July, CHRS has declined approximately 27%.
At these levels, the stock carries the elevated volatility typical of small-cap biotechnology names trading below $5, even as the underlying business reports sequential commercial growth. The gap between the current price and analyst price targets underscores the market's wait-and-see stance ahead of clinical data disclosures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Coherus BioSciences (CHRS) Business Overview and Competitive Position
Coherus BioSciences, which now operates as Coherus Oncology, is a commercial-stage immuno-oncology company headquartered in Redwood City, California. Its approved product is LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC).
The company's pipeline centers on two mid-stage candidates. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody in Phase 1b/2a studies across head and neck, colorectal, gastric, and esophageal cancers. Casdozokitug is an IL-27 antagonistic antibody in a Phase 2 first-line hepatocellular carcinoma study. Management's strategy is to grow LOQTORZI in its approved NPC indication while advancing these candidates in combination with LOQTORZI and through partners.
Investors follow CHRS for its transition from a legacy biosimilars business into a focused, innovative oncology franchise, its expanding LOQTORZI revenue base, and the binary upside tied to pipeline readouts.
Recent Developments Driving CHRS
The defining event of the past several weeks was the distribution of special CVRs tied to the company's legacy biosimilar assets. Announced August 17, 2026, the CVRs entitle holders to net proceeds from the future sale of remaining biosimilar patents, royalties, cell lines, and related materials, with a record date of September 30, 2026 and a distribution date of October 7, 2026. The move completed Coherus' transformation into a pure-play oncology company.
On the commercial side, second-quarter 2026 results reported in early August showed total revenue of $14.31 million and LOQTORZI net sales of $13.6 million, up 15% sequentially. The company reiterated full-year 2026 LOQTORZI revenue guidance of $57–62 million and ended the quarter with $105.3 million in cash, cash equivalents, and investments.
Analyst activity has remained supportive. H.C. Wainwright reiterated a Buy rating on September 21, 2026 with a $7.00 price target, following earlier Buy initiations from Guggenheim and Oppenheimer. In late October, Coherus also announced upcoming presentations at the Guggenheim and Jefferies healthcare conferences in November.
2026 Outlook and What Investors Should Watch
Heading into the remainder of 2026, the primary commercial story is whether LOQTORZI can sustain its quarter-over-quarter growth toward management's roughly $15 million per-quarter target. Sequential demand growth and account penetration remain the key execution metrics.
On the clinical front, investors are watching tagmokitug data disclosures across multiple tumor cohorts and the maturation of casdozokitug data from the fully enrolled first-line hepatocellular carcinoma study. These readouts carry meaningful binary risk given their early stage and the need for longer follow-up. From what I see, monitoring these milestones closely will be essential.
Financially, the company remains unprofitable and is relying on its cash position to fund operations through key 2026–2027 milestones, which keeps capital allocation and potential future financing decisions in focus. The next quarterly earnings report, estimated for early November 2026, will be a key checkpoint for updated guidance and pipeline timing. I’m watching this closely as the data comes in.
Exploring AI-Powered Trading Tools
In my research process, I often rely on Tickeron’s AI Trading Bots to evaluate automated strategies across different assets. The platform provides a curated view of top-performing bots, allowing comparison by strategy, timeframe, and metrics. This helps me cross-check signals on names like CHRS without depending on a single approach, offering a practical way to observe how these systems position in volatile sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CHRS in upward trend: price may jump up because it broke its lower Bollinger Band on September 24, 2026
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 43 cases where CHRS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Oscillator exited the oversold zone, 30 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 71 cases where CHRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CHRS just turned positive on October 22, 2026. Looking at past instances where CHRS's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 80 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
CHRS moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.717) is normal, around the industry mean (3.037). P/E Ratio (-1.019) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement